Generic Name and Formulations:
Serum-derived bovine immunoglobulin/protein isolate (SBI) 5g, dextrose 5g, sunflower lecithin (trace amounts); pwd; per packet; lactose-, gluten-, dye-, and soy-free.
Entera Health, Inc.
Indications for ENTERAGAM:
Clinical dietary management in patients with: limited or impaired capacity to ingest, digest, absorb, or metabolize ordinary foodstuffs or certain nutrients, or specific intestinal disorders (eg, irritable bowel syndrome with diarrhea [IBS-D], inflammatory bowel disease [IBD], and HIV-associated enteropathy).
Dissolve packet contents in at least 4oz (120mL) of water or other liquids; stir until fully mixed (do not shake); or, may be mixed in foods (eg, pudding, yogurt); consume dose immediately after mixing. Initially 1 packet twice daily for 2–4 weeks; may increase up to 4 packets daily. Maintenance: at least 1 packet daily.
<2yrs: see full labeling. ≥2yrs: Initially ½ packet daily; may increase dose based on response and tolerance.
Must use under physician supervision. Pregnancy, labor & delivery, nursing mothers: see full labeling.
Mild nausea, constipation, stomach cramps, headache, increased urination.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML